日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Revaccination with pneumococcal conjugate vaccine five years after primary immunization improves immunity in patients with chronic lymphocytic leukemia

慢性淋巴细胞白血病患者在初次免疫五年后再次接种肺炎球菌结合疫苗可提高免疫力。

Kättström, Magdalena; Uggla, Bertil; Virta, Camilla; Melin, Merit; Ekström, Nina; Magnuson, Anders; Andersson, Per-Ola; Hammarlund, Ylva; Lockmer, Sandra; Nilsson, Ingmar; Roth, Daniel; Svensson, Magnus; Tolf, Tobias; Kimby, Eva; Norén, Torbjörn; Athlin, Simon

Genetic and Microenvironment Features Do Not Distinguish Follicular Lymphoma Patients Requiring Immediate or Deferred Treatment

遗传和微环境特征无法区分滤泡性淋巴瘤患者需要立即治疗还是延迟治疗。

Stevens, Wendy B C; Los-de Vries, G Tjitske; Langois-Jacques, Carole; Clear, Andrew J; Stathi, Phylicia; Sander, Birgitta; Rosenwald, Andreas; Calaminici, Maria; Hoster, Eva; Hiddemann, Wolfgang; Gaulard, Philippe; Salles, Gilles; Klapper, Wolfram; Xerri, Luc; Burton, Catherine; Tooze, Reuben M; Smith, Alexandra G; Buske, Christian; Scott, David W; Natkunam, Yasodha; Advani, Ranjana; Sehn, Laurie H; Raemaekers, John; Gribben, John; Lockmer, Sandra; Kimby, Eva; Kersten, Marie José; Maucort-Boulch, Delphine; Ylstra, Bauke; van Dijk, Erik; de Jong, Daphne

Survival by First-line Treatment Type and Timing of Progression Among Follicular Lymphoma Patients: A National Population-based Study in Sweden

瑞典一项基于全国人口的研究:滤泡性淋巴瘤患者一线治疗类型及疾病进展时间与生存率的关系

Weibull, Caroline E; Wästerlid, Tove; Wahlin, Björn Engelbrekt; Andersson, Per-Ola; Ekberg, Sara; Lockmer, Sandra; Enblad, Gunilla; Crowther, Michael J; Kimby, Eva; Smedby, Karin E

Minimal residual disease status is the prognostic determinant following high-dose treatment for patients with multiple myeloma

微小残留病灶状态是多发性骨髓瘤患者接受大剂量治疗后的预后决定因素。

Nahi, Hareth; Afram, Gabriel; Uttervall, Katarina; Lockmer, Sandra; Tätting, Love; Gahrton, Gösta; Kashif, Muhammad; Alici, Evren; Stromberg, Olga; Klimkowska, Monika; Lund, Johan

Antibody response to COVID-19 mRNA vaccine (Comirnaty) in myeloma patients treated with high-dose melphalan and/or immunotherapy

接受高剂量美法仑和/或免疫疗法治疗的多发性骨髓瘤患者对 COVID-19 mRNA 疫苗(Comirnaty)的抗体反应

Lockmer, Sandra; Uttervall, Katarina; Kashif, Muhammad; Svärd, Carina; Malmsten, Katarina; Fletcher-Torres, Evellyn; Alici, Evren; Lund, Johan; Nahi, Hareth

Absolute B cell counts in blood predict long-term response in follicular lymphoma patients treated with rituximab without chemotherapy

血液中绝对B细胞计数可预测接受利妥昔单抗治疗(未接受化疗)的滤泡性淋巴瘤患者的长期疗效。

Junlén, Henna-Riikka; Lockmer, Sandra; Kimby, Eva; Wahlin, Björn Engelbrekt

A clinico-molecular predictor identifies follicular lymphoma patients at risk of early transformation after first-line immunotherapy

临床分子预测因子可识别一线免疫治疗后有早期转化风险的滤泡性淋巴瘤患者

Steen, Chloé B; Leich, Ellen; Myklebust, June H; Lockmer, Sandra; Wise, Jillian F; Wahlin, Björn E; Østenstad, Bjørn; Liestøl, Knut; Kimby, Eva; Rosenwald, Andreas; Smeland, Erlend B; Holte, Harald; Lingjærde, Ole Christian; Brodtkorb, Marianne